SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending as community members discuss its potential involvement with the U.S. government and the strategic importance of its Greenland rare earth deposits. Investors are evaluating the company's increased ownership stake in the Tanbreez project, while some highlight the relationship between CRML and European Lithium (EULIF) and its possible undervaluation. Overall, the conversation centers on CRML's position in the critical minerals sector and potential catalysts for future growth.

This is a legacy token commemorating the pseudonym Satoshi Nakamoto.

Satoshi Nakamoto

$SATOSHI is trending as the community rallies around its potential as the 'Bitcoin of memes' and a representation of the entire crypto industry. Discussions highlight the token's timeless narrative centered on Satoshi Nakamoto, the pseudonymous creator of Bitcoin, and its strong community. Some users are celebrating the project's two-year anniversary.

Reactive Network is the first parallelized interoperability execution layer, utilising a new form of smart contract we call reactive smart contracts.   Reactive smart contracts are able to react to on-chain events autonomously and execute their own user defined logic to initiate new transactions. This allows a virtually limitless number of use cases to achieve fully decentralized on-chain automation.

Reactive Network

Reactive Network is trending as community members discuss its potential, citing upcoming catalysts and integrations. There's excitement around the sunsetting of $PRQ and anticipation for new exchange listings. Community members highlight the project's utility and low supply, expressing long-term bullish sentiment.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending due to anticipation surrounding potential public flights of its Midnight aircraft at the California International Air Show, sparking community debate on whether the company will demonstrate vertical takeoff capabilities. Some investors express confidence in upcoming catalysts, while others compare Archer's progress and market position to competitors like Joby Aviation. Discussions also include speculation around potential partnerships, particularly with Tesla, and the impact of government shutdowns on FAA approvals.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as the community emphasizes the cultural significance and longevity of weed culture. Some users are drawing parallels to Bitcoin, while others highlight the coin's potential and encourage others to invest. Community members are sharing links to the Weedcoin website and DEX screeners.

Amicus Therapeutics, Inc. is a biotechnology company, which focuses on discovering, developing, and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Princeton, NJ.

Amicus Therapeutics Inc

FOLD is trending as investors discuss the potential impact of trial outcomes and settlement possibilities, with community members weighing the likelihood of a deal. Analyst ratings have recently been updated, contributing to the stock's activity. Some see FOLD as undervalued compared to peers, particularly when considering revenue multiples and potential M&A scenarios.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MLTX is trending as the community discusses a potential overreaction to recent trial data and what it means for future FDA approval. Bullish investors are pointing to strong secondary endpoints and a large options contract as signs of an impending rise, while bears cite negative financials and skepticism around the drug's efficacy. Chatter revolves around whether the stock is undervalued and if a potential buyout by Merck could be back on the table.

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.

Insulet Corporation

Insulet (PODD) is trending amid unusual options activity and community discussion around potential ROI from call options. Some analysts believe recent product approvals may drive growth, while others note bearish put flow, with community members sharing both bullish and bearish sentiments regarding the stock's prospects. The stock has seen impressive gains over the past year, and investors are currently assessing the drivers behind this rally, including international expansion and adoption of its Omnipod 5 system.

Mind Medicine (MindMed), Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Mind Medicine Inc

Mind Medicine Inc - Ordinary Shares (Sub Voting)

MNMD is trending as community members discuss the company's progress in clinical trials and potential market opportunities in the psychedelic treatment space. Bullish sentiment is fueled by discussions around market capitalization, institutional investment, and upcoming catalysts related to trial readouts and regulatory interactions. Some traders are also noting technical indicators, suggesting a potential for upward price movement.

Valvoline, Inc. engages in the production, marketing, and supply of engine and automotive maintenance products and services. It operates through the Retail Services segment. The Retail Services segment services the passenger car and light truck quick lube market in the US and Canada with preventive maintenance services done through company operated and independent franchise care stores. The company was founded by John Ellis in 1866 and is headquartered in Lexington, KY.

Valvoline Inc

Valvoline is trending as community members discuss the potential for the stock to test all-time highs, driven by planned store openings and expansion into electric vehicle services. Many see it as a safe, long-term hold with financial AI analysis supporting its health. Bullish sentiment is fueled by significant buy orders and expectations for a positive run in the coming weeks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

DaVita HealthCare (DVA) is a Top-Ranked Growth Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why DaVita HealthCare (DVA) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

DaVita HealthCare (DVA) Rises Higher Than Market: Key Facts

In the latest trading session, DaVita HealthCare (DVA) closed at $132.87, marking a +1.75% move from the previous day.

Zacks Industry Outlook Highlights Quest Diagnostics, DaVita, Addus HomeCare and The Pennant

Quest Diagnostics, DaVita, Addus HomeCare, and The Pennant Group are positioned to benefit from telehealth, AI adoption, and rising demand in the $747B home healthcare market.

4 Outpatient Home Health Stocks Worth Watching Amid Shifting Trends

An aging global population and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry despite the macroeconomic challenges. DGX, DVA, ADUS and PNTG are well-poised to gain.

DaVita HealthCare (DVA) Gains As Market Dips: What You Should Know

The latest trading day saw DaVita HealthCare (DVA) settling at $132.83, representing a +1.28% change from its previous close.

Should Value Investors Buy DaVita (DVA) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

DaVita HealthCare (DVA) Sees a More Significant Dip Than Broader Market: Some Facts to Know

In the latest trading session, DaVita HealthCare (DVA) closed at $128, marking a -1.62% move from the previous day.

Why DaVita HealthCare (DVA) is a Top Growth Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

DaVita HealthCare (DVA) Stock Drops Despite Market Gains: Important Facts to Note

DaVita HealthCare (DVA) closed at $132.26 in the latest trading session, marking a -3.26% move from the prior day.

DaVita, Inc. engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consist primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.

DaVita Inc

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

DVA
DaVita Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest DVA News

DVA DaVita Inc